Status:
UNKNOWN
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborating Sponsors:
CytoSorbents, Inc
Conditions:
Septic Shock
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This prospective randomized single center study investigates to what extent the removal of elevated cytokine levels by hemoadsorption has a positive effect on the treatment of patients in septic shock...
Detailed Description
The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are...
Eligibility Criteria
Inclusion
- Refractory septic shock
- Need for Norepinephrine ≥ 0.25 µg/kg/min
- IL6 ≥ 1000 ng/l
- Indication for CRRT
Exclusion
- Sepsis due to pulmonary or urogenital causes
- Onset of septic shock longer than 36 hours
- Liver cirrhosis Child Pugh C
- "do not resuscitate"-order
- expected survival \< 14 days
- participation in another interventional trial
- Pregnancy or breastfeeding
- Lack of consent
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04013269
Start Date
January 1 2020
End Date
December 1 2023
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Hamburg-Eppendorf
Hamburg, Germany